Compare DAIO & LSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DAIO | LSTA |
|---|---|---|
| Founded | 1969 | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Misc Health and Biotechnology Services |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.2M | 28.9M |
| IPO Year | 2026 | 2000 |
| Metric | DAIO | LSTA |
|---|---|---|
| Price | $3.17 | $1.06 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 2 |
| Target Price | $5.22 | ★ $15.00 |
| AVG Volume (30 Days) | 38.4K | ★ 121.5K |
| Earning Date | 05-14-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 20.42 |
| EPS | ★ N/A | N/A |
| Revenue | $21,500,000.00 | ★ $35,283,868.00 |
| Revenue This Year | $4.51 | N/A |
| Revenue Next Year | $30.29 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 56.90 |
| 52 Week Low | $2.16 | $0.99 |
| 52 Week High | $4.49 | $5.07 |
| Indicator | DAIO | LSTA |
|---|---|---|
| Relative Strength Index (RSI) | 37.55 | 19.37 |
| Support Level | $2.60 | N/A |
| Resistance Level | $3.26 | $2.19 |
| Average True Range (ATR) | 0.19 | 0.20 |
| MACD | -0.00 | -0.08 |
| Stochastic Oscillator | 29.31 | 3.23 |
Data I/O Corp provides semiconductor programming, security provisioning, and intellectual property protection and management solutions used in electronics manufacturing with flash memory, microcontrollers, and flash memory-based intelligent devices as well as secure element devices, authentication devices and secure microcontrollers. It operates as a single segment entity, with the sole objective to design, manufacture, and sell programming solutions and Programming-as-a-Service (PaaS) to the world's various electronics manufacturers including OEMs, CMs and EMS companies. The company operate in three separate locations Redmond, Washington; Shanghai, China; and Munich, Germany.
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The company has one operating segment, the research and development of its investigational drug product.